Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641090 | 0.93 | MEN1 (0.70) | TSHRMEN1KMT2ANOD2NPC1 | |
| SCHEMBL13641087 | 0.93 | MEN1 (0.70) | TSHRMEN1KMT2ANOD2NPC1 | |
| SCHEMBL13641117 | 0.88 | HTT (0.71) | TSHRMEN1KMT2ANOD2NPC1 | |
| SCHEMBL13640907 | 0.86 | HTT (0.63) | TSHRMEN1KMT2ALIMK1KDM4E | |
| SCHEMBL13640909 | 0.86 | HTT (0.60) | TSHRMEN1KMT2ALIMK1KDM4E | |
| SCHEMBL13641206 | 0.83 | MEN1 (0.53) | TSHRMEN1KMT2ANOD2NPC1 | |
| SCHEMBL16406296 | 0.83 | MEN1 (0.71) | TSHRMEN1KMT2ANOD2NPC1 | |
| SCHEMBL19444621 | 0.82 | MEN1 (0.70) | TSHRMEN1KMT2ANOD2NPC1 | |
| SCHEMBL13641151 | 0.81 | MEN1 (0.46) | TSHRMEN1KMT2ANOD2NPC1 | |
| SCHEMBL10343720 | 0.78 | HTT (0.73) | TSHRMEN1KMT2ANOD2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9212190-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212190-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20130231328-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231328-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3940/4885MEN1 3741/4885KMT2A 653/4885 |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3940/4885MEN1 3741/4885KMT2A 653/4885 |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3940/4885MEN1 3741/4885KMT2A 653/4885 |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3940/4885MEN1 3741/4885KMT2A 653/4885 |
| US-20130231328-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3940/4885MEN1 3741/4885KMT2A 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.